Finasteride MK

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Finasteride MK

Quick Facts

Property Description
Active ingredient Finasteride
Form Solid oral tablet
Pharmacological class 5alpha-reductase inhibitor
General purpose Modulating hormonal activity by reducing DHT
Origin Synthetic aza-steroid compound

What Type of Medicine is Finasteride MK?

Finasteride MK is a synthetic, single-ingredient prescription medicine classified pharmacologically as a 5alpha-reductase inhibitor. The drug’s active substance, Finasteride, is an aza-steroid compound, which establishes its chemical structure and origin. This classification indicates the medicine is designed to target specific hormonal pathways in adult males, a role confirmed by its categorization within the antiandrogen class of therapeutic agents.

Unlike certain medications that broadly affect hormone receptors, Finasteride is differentiated by its specific targeting of an enzyme. This action makes it a highly selective systemic therapy, clinically recognized for its ability to regulate processes influenced by potent androgens.


Composition, Form, and General Purpose

The medication is formulated as a solid oral tablet for systemic administration, ensuring controlled absorption of the active ingredient, Finasteride, alongside necessary inactive excipients. Finasteride functions as a competitive and specific inhibitor of the Type II 5alpha-reductase enzyme, which is primarily responsible for converting testosterone into the more potent androgen, dihydrotestosterone (DHT).

The general therapeutic purpose of this drug is to modulate steroid metabolism by reliably reducing serum and tissue concentrations of DHT. A typical scenario involves using Finasteride to address biological processes where DHT contributes to the enlargement of the prostate gland. By consistently lowering the concentration of this potent androgen, the medicine provides a targeted approach to managing biological activities within susceptible tissues.

Regulatory References

  1. Finasteride Overview - MedlinePlus, NIH

What side effects are possible with Finasteride MK?

Possible Side Effects and Safety Information

Finasteride MK's safety profile, as outlined by regulatory authorities, centers on adverse reactions categorized by frequency and the body system affected. The most frequently documented adverse reactions occur within the Reproductive System and Breast Disorders and Psychiatric Disorders categories.

Sexual side effects are the most common official findings, often occurring early in treatment. In regulatory documents, erectile dysfunction is classified as Very Common (particularly for the 5 mg dose), while decreased libido and ejaculation disorders are classified as Common.

Less frequent, or Uncommon, effects include gynecomastia (breast enlargement and/or tenderness) and rash. Effects such as depression, testicular pain, and various hypersensitivity reactions (e.g., swelling of the lips and face) have been reported post-marketing and are classified as having a Not Known frequency.

Documented Serious Safety Considerations

The official label includes warnings about two rare but significant considerations. Post-marketing reports have documented cases of male breast cancer. Additionally, regulatory documentation notes an increased risk of high-grade prostate cancer in men aged 55 and older when taking the 5 mg dose, compared to placebo.

Population and Duration-Related Safety

Finasteride is strictly contraindicated in women who are or may be pregnant due to the risk of abnormal development of the external genitalia in a male fetus. Pregnant or potentially pregnant women are cautioned against handling crushed or broken tablets. While most sexual side effects may resolve with continued use, regulatory reports document that sexual dysfunction has been reported to persist in some individuals even after discontinuing the medicine. Finasteride is also known to cause a predictable sim 50% decrease in Prostate Specific Antigen (PSA) levels, which must be accounted for during cancer screening evaluations.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation provides specific guidance on Finasteride overdose, focusing on documented clinical trial experience and required emergency actions. The information is strictly based on the FDA, EMA, and other authoritative government health sources.

Documented Overdose Profile

Feature Official Regulatory Statement
Documented Manifestations None specified. Clinical studies have administered Finasteride at single doses up to 400 mg and multiple daily doses up to 80 mg for three months without resulting in specific adverse effects or symptoms attributed to acute overdose.
Antidote Availability No specific antidote is known for Finasteride overdose.
Management Strategy The required official procedure is symptomatic and supportive treatment.

Emergency Actions Mandated by Regulators

The most important action is to seek immediate medical attention for any suspected overdose event. Since no specific manifestations are consistently documented, seeking help is a required precaution for exposure to doses higher than prescribed. The absence of a specific antidote dictates that medical management will focus on providing supportive care and general observation, as is standard practice for drug exposures lacking a reversal agent. This approach aligns with official regulatory directives found in prescribing information globally.

Therapeutic Uses of Finasteride MK

What Finasteride MK Treats: Main Uses and Benefits

The key therapeutic domains for Finasteride MK involve two common condition categories in men. The medication is applied across domains where additional symptomatic support is needed for symptomatic Benign Prostatic Hyperplasia (BPH) and the management of male pattern hair loss.


Support for Symptomatic BPH

This domain covers symptoms related to physical discomfort linked to the enlarged prostate. Finasteride MK is commonly used to help address symptom clusters that may become intense or disruptive, such as frequent urination, urgency, and a weak stream. It provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms. It supports the patient during difficult episodes by easing distress.

“Applied in clinical settings that involve acute or unstable symptom patterns, it is relevant when supportive symptom management is appropriate.”

Quick Fact: Relevant for Urinary Symptoms


Management of Male Pattern Hair Loss

This second use is relevant in contexts marked by increased discomfort or tension related to the gradual thinning and recession of scalp hair (androgenetic alopecia). It helps address symptoms that create noticeable functional strain regarding appearance and may assist with maintaining existing hair in conditions where symptoms escalate temporarily. It is applied in situations involving certain distressing symptoms where short-term symptom management is appropriate.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility for Finasteride MK: Official Regulatory Status

Finasteride MK is strictly indicated for use in adult men for its approved conditions, with eligibility defined by specific regulatory constraints. The official labeling specifies groups who must be excluded from treatment, based on gender, age, and pre-existing conditions.

Populations Prohibited from Use (Contraindicated)

This medicine is contraindicated in women, especially those who are or may potentially be pregnant, due to the potential risk of external genital abnormalities in a male fetus. Use is not indicated for females in any capacity. The drug is also contraindicated for individuals with a known hypersensitivity to finasteride or any component of the formulation. Pregnant women must not handle crushed or broken tablets.

Age and Organ Function Eligibility

Finasteride MK is not indicated for use in pediatric patients (under 18 years) as safety and efficacy have not been established by regulatory authorities. For older-adult men and men with renal impairment, regulatory documents state no dosage adjustment is necessary. However, because the drug is metabolized extensively in the liver, caution should be used in patients with liver function abnormalities.


Connection to the Overall Eligibility Profile

Regulatory documents define the user base for Finasteride MK as exclusively adult men. Absolute contraindications restrict the medicine's use in all women (especially during pregnancy) and in individuals with known hypersensitivity.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Finasteride MK is officially documented and primarily addresses potential changes in drug exposure and specific co-administration restrictions.


Restrictions and Combination Rules

Finasteride MK must not be taken concurrently with any other 5α-reductase inhibitor (such as Dutasteride). This restriction is applied to prevent the co-administration of two agents that act via the same primary pharmacological mechanism, as noted in the regulatory labeling.


Interactions Affecting Drug Exposure

Finasteride is primarily processed by the Cytochrome P450 3A4 (CYP3A4) enzyme system. Co-administration with other medicines classified as strong CYP3A4 inhibitors may increase the plasma concentration (exposure) of Finasteride. Conversely, strong CYP3A4 inducers are expected to decrease Finasteride exposure, based on the documented metabolic pathway.


Clinically Insignificant Interactions

Official regulatory studies have concluded that Finasteride does not produce clinically significant drug-drug interactions when co-administered with several common medicines. These tested compounds include Digoxin, Warfarin, Propranolol, Theophylline, Glibenclamide, and Antipyrine.


Food and Population Notes

Finasteride may be taken with or without food, as meals do not produce a clinically relevant interaction with its absorption. Official labeling notes that the effect of severe hepatic impairment (liver disease) on Finasteride clearance has not been formally studied.

Mechanism of Action

Specific Inhibition of the DHT Synthesis Pathway

This molecule functions as a selective, competitive inhibitor of the Type II 5alpha-reductase enzyme. This mechanism directly blocks the enzymatic step responsible for converting Testosterone into the androgen, dihydrotestosterone (DHT), thereby reducing the synthesis of this androgen in target tissues.

The Mechanism of Tissue Atrophy

The resulting reduction in DHT concentration, both systemically and locally, modulates cellular signaling within androgen-sensitive tissues. Over time, this reduced androgenic drive causes susceptible cells to undergo atrophy (shrinkage), which is the underlying physiological process by which the drug produces a corresponding physiological change in tissue volume.

Constraints on Full Androgen Suppression

The mechanism is constrained by the drug's lower binding affinity for the Type I 5alpha-reductase isoform. This distinction means that DHT production mediated by the Type I enzyme (found in skin and liver) is less affected, resulting in the characteristic, incomplete overall suppression of DHT levels.

Dosage and Administration Information

How to Use Finasteride (1 mg and 5 mg)

The following instructions summarize the official administration guidelines for Finasteride.

Finasteride is administered orally and must be taken as a single, consistent daily dose.

Official Dosing and Frequency

Indication Tablet Strength Dosing Schedule
Benign Prostatic Hyperplasia (BPH) 5 mg One tablet once daily
Male Pattern Hair Loss 1 mg One tablet once daily

Administration Requirements

Finasteride tablets should be swallowed whole and must not be crushed or broken. The tablets may be taken with or without meals. Consistent daily use, preferably at approximately the same time each day, is required.

Procedural and Population Constraints

Missed Dose: If a dose is missed, it should be skipped, and the patient should resume the regular schedule with the next scheduled dose; double doses should not be taken.

Handling Restriction: Pregnant or potentially pregnant women must not handle crushed or broken Finasteride tablets due to the risk of absorption and potential harm to a male fetus.

Dosage Adjustment: No dosage adjustment is necessary for geriatric patients or for patients with renal impairment. Finasteride is not indicated for use in pediatric patients.

Recent Clinical Evidence

Evidence for use in Symptomatic Benign Prostatic Hyperplasia (BPH)

The research exploring Finasteride MK in the context of symptomatic BPH relies on large-scale, long-running Randomized Controlled Trials (RCTs) and Systematic Reviews. These multi-center studies compared measured parameters in patients receiving the study product versus controls over defined periods. Researchers monitored parameters related to physical discomfort, assessing changes in urinary symptom scores and prostate volume. Long-term trials described patterns observed in clinical progression events like acute urinary retention or the need for surgery.

Evidence for use in Male Pattern Hair Loss (Androgenetic Alopecia)

Studies explored Finasteride MK in the context of male pattern hair loss using placebo-controlled, double-blind RCTs. These trials included adult men with mild-to-moderate thinning and examined changes over short and intermediate intervals. Researchers monitored scalp hair counts and utilized Global Photographic Assessment by expert panels. Trials reported how these objective parameters evolved over time, with subsequent extension studies monitoring parameters for up to ten years.

Durability, Subgroups, and Uncertainty

The research includes long-term follow-up for BPH (up to four years) and hair loss (up to ten years) to assess the sustained evolution of measured parameters. Subgroup analyses examined how parameters evolved for men based on factors like baseline prostate size or advanced hair loss severity. The research consistently described that measured parameters returned toward baseline after the study product was stopped. Evidence is limited for long-term outcomes in some quality-of-life measures, and results apply only to the populations studied.

Key Studies & References

  1. The medical treatment of benign prostatic hyperplasia study (MTOPS): a 1-year analysis of the combination of doxazosin and finasteride

Frequently Asked Questions (FAQ)

Common questions about Finasteride MK (FAQ)


Q: Will I lose all the hair I gained if I stop taking Finasteride MK?

A: Studies and official information indicate that the beneficial effects of the medicine on hair growth are reversed when treatment is discontinued. The improvements are generally expected to return toward the pre-treatment baseline condition, with this reversal typically observed within 12 months.


Q: How long does it usually take to see visible results from Finasteride MK for hair loss?

A: According to the official product information, consistent daily use for a period of three months or more is generally required before any noticeable benefit on hair growth or slowing of hair loss is typically observed.


Q: What is 'Post-Finasteride Syndrome' and is it officially recognized?

A: While the specific term 'Post-Finasteride Syndrome' is not generally used in regulatory adverse reaction lists, official product information does note a safety concern. Certain side effects, particularly sexual dysfunction, have been reported to persist in some individuals even after they have stopped taking the medicine.


Q: Is it possible for the common side effects of Finasteride MK to continue after stopping the medication?

A: Regulatory reports document that sexual dysfunction, such as decreased libido (sex drive) and erectile dysfunction, has been reported to continue in some individuals after discontinuing the medicine. Most other side effects typically resolve once treatment stops.


Q: Are side effects more likely to occur with the higher dose (for prostate) or the lower dose (for hair loss)?

A: Adverse reaction data in official documents indicate that the likelihood of certain side effects can differ between the two doses. For example, erectile dysfunction is classified as Very Common for the 5 mg dose used for an enlarged prostate, but only Common for the 1 mg dose used for hair loss.


Q: Why is it recommended to tell my doctor if I plan to have children while on Finasteride MK?

A: Official product information mentions that the effect on fertility in men has not been fully studied. There have been post-marketing reports where some men have experienced poor sperm quality or infertility, which typically reversed upon stopping the medicine.


Q: Is there a specific way the Finasteride MK tablet must be swallowed?

A: The tablets must always be swallowed whole and should not be crushed or broken. Official patient information advises taking the tablet with a drink of water, and it can be taken with or without food.


Q: What is the main difference between Finasteride MK and Minoxidil?

A: Finasteride’s documented mechanism of action is to selectively inhibit a specific enzyme to reduce the formation of the hormone dihydrotestosterone (DHT). Minoxidil, in contrast, is classified as a medicine that promotes hair growth through different, unrelated pathways.


Q: Does Finasteride MK only work on the crown of the head, or does it also help the hairline?

A: Clinical trials supported the medicine's effectiveness in men with hair loss in the vertex (crown) and the anterior mid-scalp area. However, official labeling notes that efficacy in bitemporal recession (hair loss at the temples/receding hairline) has not been definitively established.


Q: Is Finasteride MK effective for women who have hair loss?

A: Finasteride is indicated solely for the treatment of male pattern hair loss in men. It is not indicated for use in women, and it is strictly forbidden for women who are or may be pregnant, due to a risk of potential harm to a male fetus.


Q: Is Finasteride MK the same as Propecia or Proscar?

A: Finasteride is the active ingredient in the medicine. Propecia and Proscar are brand names for products containing Finasteride. Propecia generally refers to the 1 mg dose (for hair loss), while Proscar typically refers to the 5 mg dose (for an enlarged prostate).


Q: Does taking Finasteride MK affect the body hair on other parts of the body?

A: Regulatory information indicates that while the medicine is expected to increase the number of scalp hairs, it will not increase the amount of hair on other parts of the body.


Q: Is Finasteride MK safe to take for many years as a long-term treatment?

A: To maintain its effects, the medicine is intended for continued use. Clinical data includes long-term studies lasting up to five years or more. Regulatory documents outline known long-term risks, such as the increased risk of a rare form of prostate cancer and the possibility of persistent sexual dysfunction.


Q: Does Finasteride MK cause an increase in testosterone levels?

A: Because the medicine blocks the conversion of Testosterone into DHT, the circulating levels of Testosterone in the blood are expected to increase. Official data indicates this increase is small, approximately 10 % to 20 %, and remains within the normal physiologic range.


Q: Can Finasteride MK affect fertility or sperm count in men?

A: Some men using the medicine have reported poor semen quality, including low sperm count. This is not a common side effect, and the reported effects on sperm quality usually return to normal after stopping the treatment.


Q: Can older men over 70 still use Finasteride MK, and are there special considerations?

A: Official product information states that no specific dosage adjustment is necessary for elderly patients. However, studies show that the medicine is eliminated from the body more slowly in men over 70 years of age.


Q: What is the main difference in how Finasteride MK treats an enlarged prostate versus hair loss?

A: The medicine uses the same mechanism—reducing the level of the hormone DHT—to treat two different conditions. For an enlarged prostate, the goal is to reduce the size of the gland; for hair loss, the goal is to increase hair growth and slow hair loss on the scalp.


Q: Can I drive or operate machinery while taking Finasteride MK?

A: Official regulatory documents and safety data indicate there are no known data or warnings to suggest that Finasteride affects a person’s ability to drive or use machinery safely.


Q: Is Finasteride MK used for hair loss on the temples or bitemporal recession?

A: The clinical trials that supported the medicine's efficacy demonstrated results for the crown and mid-scalp areas. Official labeling explicitly states that effectiveness in bitemporal recession, which refers to the receding hairline and temples, has not been established.


Q: Does Finasteride MK cause weight gain or weight loss?

A: Weight changes (either gain or loss) are not classified in official documents as common, uncommon, or rare side effects. However, these effects have been reported in post-marketing experience, and their frequency is classified as 'Not Known.'


Q: Can I take Finasteride MK if I have a history of liver problems?

A: Since the medicine is processed in the liver, regulatory documents state that caution is necessary when the medicine is used in patients with known liver function abnormalities. The effect of severe liver impairment on the medicine's clearance has not been formally studied.


Q: How long does the effect of Finasteride MK last after a single dose?

A: Pharmacokinetic data shows that a single oral dose produces a rapid decrease in the target hormone, DHT, with the maximum suppression observed within 8 hours. This reduction in the hormone level is maintained for at least 24 hours.


Q: Does Finasteride MK work by causing existing hair to grow or by regrowing new hair?

A: The mechanism of reducing DHT aims to reverse the miniaturization process of hair follicles caused by the hormone. Clinical trial data showed an increase in overall hair counts, supporting that the medicine works by promoting the growth of existing hairs and supporting new growth.


Q: Are dizziness or lightheadedness common side effects when starting Finasteride MK?

A: Official side effect classifications do not list dizziness or lightheadedness as a common adverse reaction. However, these effects have been reported in post-marketing experience, and their frequency is classified as 'Not Known' due to a lack of frequency data from controlled trials.


Q: Are there any restrictions on donating blood while taking Finasteride MK?

A: Official blood donation guidelines state that a person taking Finasteride generally cannot donate blood for a specified period (often 1 month) after their last dose. This measure is in place to prevent the risk of exposing a pregnant recipient to the medicine through the donated blood.


Q: Is it necessary to inform a sexual partner about Finasteride MK use?

A: Official guidance notes that trace amounts of the medicine have been found in the semen of men taking it. Manufacturers advise using a condom if the sexual partner is pregnant or potentially pregnant, although the actual risk to the fetus is described as unlikely to be significant.


Q: Can Finasteride MK be used to treat hair loss that is not male pattern baldness?

A: The medicine is indicated only for the treatment of male pattern hair loss, also known as androgenetic alopecia. Official labeling does not support its use for other types of hair loss.


Q: What is the role of the hormone DHT in the conditions Finasteride MK is used for?

A: Dihydrotestosterone (DHT) is an androgen (male hormone) that is involved in the development and progression of both benign prostatic hyperplasia (BPH) and male pattern hair loss. Finasteride's core action is to reduce the levels of this specific hormone.

How should Finasteride MK be stored and disposed of?

Finasteride tablets must be stored under specific environmental conditions to maintain stability and are subject to mandatory handling precautions.

Official Storage and Handling

Requirement Area Labeled Constraint
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection Keep in the original container, tightly closed, and protect from light and moisture. Avoid storage in areas of excess heat and humidity.
Child Safety The medication must be kept out of the sight and reach of children.
Special Handling Pregnant women must not handle crushed or broken tablets due to the potential risk of absorption of the active ingredient and subsequent harm to a male fetus.

Disposal Requirements

Unused or expired tablets must be disposed of in accordance with local requirements; they should not be flushed down the toilet or drain. Utilize community drug take-back programs or follow the FDA's guidance for disposal in household trash by mixing the medication with an undesirable substance (e.g., used coffee grounds) in a sealed bag.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Finasteride MK found in:

A-Z Index: